Cardiac Protective Effect of Terminalia muelleri Extract in Rat Model of Diabetes Mellitus

Cardiovascular disease is the major cause of morbidity and mortality in people with type 2 diabetes. The present study aims to evaluate the cardiac protective effect of Terminalia muelleri (TM) in diabetic rats. Treatment of diabetic rats with a daily oral dose of (TM) extract (200 mg/kg b.wt) or pioglitazone tablet (1.58 mg/kg b.wt) for four weeks resulted in a significant decrease in the glucose, total cholesterol (TC), triglycride (TG), low density lipoprotein cholesterol (LDL-C), malondialdehyde (MDA), aspartate amino transferase (AST) and creatin kinase-MB (CK-MB) activities as well as homocysteine (Hcy) and troponin-1 (cTn-1) levels in association with a significant increase in high density lipoprotein cholesterol (HDL-C) level, glutathione (GSH) content and nuclear factor-erythroid factor 2-related factor 2 (Nrf2) level when compared with diabetic rats. These data suggest that TM might be an effective antidiabetic agent in the prevention of diabetic complication. TM extract could help in combating against oxidation damage in cardiac tissue.